Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 240

1.

Impact of the Choice of IGF-I Assay and Normative Dataset on the Diagnosis and Treatment of Growth Hormone Deficiency in Children.

Broeren MAC, Krabbe JG, Boesten LS, Hokken-Koelega ACS, de Rijke YB.

Horm Res Paediatr. 2018 Oct 4:1-9. doi: 10.1159/000493133. [Epub ahead of print]

PMID:
30286459
2.

Gonadal function and pubertal development in patients with Silver-Russell syndrome.

Goedegebuure WJ, Smeets CCJ, Renes JS, de Rijke YB, Hokken-Koelega ACS.

Hum Reprod. 2018 Nov 1;33(11):2122-2130. doi: 10.1093/humrep/dey286.

PMID:
30252068
3.

Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort.

Swerdlow AJ, Cooke R, Beckers D, Butler G, Carel JC, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse E, Hokken-Koelega ACS, Khan AJ, Kiess W, Kuehni CE, Flück CE, Pfaffle R, Sävendahl L, Sommer G, Thomas M, Tidblad A, Tollerfield S, Zandwijken GRJ.

J Clin Endocrinol Metab. 2018 Aug 17. doi: 10.1210/jc.2018-01133. [Epub ahead of print]

PMID:
30137467
4.

Improved Mental and Motor Development During 3 Years of GH Treatment in Very Young Children With Prader-Willi Syndrome.

Donze SH, Damen L, Mahabier EF, Hokken-Koelega ACS.

J Clin Endocrinol Metab. 2018 Oct 1;103(10):3714-3719. doi: 10.1210/jc.2018-00687.

PMID:
30113638
5.

Children born small for gestational age: differential diagnosis, molecular-genetic evaluation and implications.

Finken MJJ, van der Steen M, Smeets CCJ, Walenkamp MJE, de Bruin C, Hokken-Koelega ACS, Wit JM.

Endocr Rev. 2018 Jul 4. doi: 10.1210/er.2018-00083. [Epub ahead of print]

PMID:
29982551
6.

Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.

Donze SH, Kuppens RJ, Bakker NE, van Alfen-van der Velden JAEM, Hokken-Koelega ACS.

Clin Endocrinol (Oxf). 2018 Jun;88(6):806-812. doi: 10.1111/cen.13567. Epub 2018 Mar 22.

PMID:
29418016
7.

Low FT4 Concentrations around the Start of Recombinant Human Growth Hormone Treatment: Predictor of Congenital Structural Hypothalamic-Pituitary Abnormalities?

van Iersel L, van Santen HM, Zandwijken GRJ, Zwaveling-Soonawala N, Hokken-Koelega ACS, van Trotsenburg ASP.

Horm Res Paediatr. 2018;89(2):98-107. doi: 10.1159/000486033. Epub 2018 Jan 18.

8.

Genetic screening of regulatory regions of pituitary transcription factors in patients with idiopathic pituitary hormone deficiencies.

Elizabeth M, Hokken-Koelega ACS, Schuilwerve J, Peeters RP, Visser TJ, de Graaff LCG.

Pituitary. 2018 Feb;21(1):76-83. doi: 10.1007/s11102-017-0850-6.

9.

Impact of Early Infant Growth, Duration of Breastfeeding and Maternal Factors on Total Body Fat Mass and Visceral Fat at 3 and 6 Months of Age.

Breij LM, Abrahamse-Berkeveld M, Acton D, De Lucia Rolfe E, Ong KK, Hokken-Koelega ACS.

Ann Nutr Metab. 2017;71(3-4):203-210. doi: 10.1159/000481539. Epub 2017 Nov 14.

PMID:
29136614
10.

Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study.

van der Steen M, Kerkhof GF, Smeets CCJ, Hokken-Koelega ACS.

Lancet Diabetes Endocrinol. 2017 Dec;5(12):975-985. doi: 10.1016/S2213-8587(17)30311-X. Epub 2017 Nov 1.

PMID:
29102566
11.

Bone Mineral Density After Cessation of GH Treatment in Young Adults Born SGA: A 5-Year Longitudinal Study.

Smeets CCJ, van der Steen M, Renes JS, Hokken-Koelega ACS.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3508-3516. doi: 10.1210/jc.2017-00269.

PMID:
28911145
12.

Foetal fractional thigh volume: an early 3D ultrasound marker of neonatal adiposity.

Roelants JA, Vermeulen MJ, Koning IV, Groenenberg IAL, Willemsen SP, Hokken-Koelega ACS, Joosten KFM, Reiss IKM, Steegers-Theunissen RPM.

Pediatr Obes. 2017 Aug;12 Suppl 1:65-71. doi: 10.1111/ijpo.12231. Epub 2017 Jul 28.

PMID:
28752648
13.

Genetic analysis of IRF6, a gene involved in craniofacial midline formation, in relation to pituitary and facial morphology of patients with idiopathic growth hormone deficiency.

Starink E, Hokken-Koelega ACS, Visser TJ, Baan J, Peeters RP, de Graaff LCG.

Pituitary. 2017 Oct;20(5):499-508. doi: 10.1007/s11102-017-0808-8.

14.

Aberrant White Matter Microstructure in Children and Adolescents With the Subtype of Prader-Willi Syndrome at High Risk for Psychosis.

Lukoshe A, van den Bosch GE, van der Lugt A, Kushner SA, Hokken-Koelega AC, White T.

Schizophr Bull. 2017 Sep 1;43(5):1090-1099. doi: 10.1093/schbul/sbx052.

15.

Does prednisone use or disease activity in pregnant women with rheumatoid arthritis influence the body composition of their offspring?

de Steenwinkel FDO, Dolhain RJEM, Hazes JMW, Hokken-Koelega ACS.

Reprod Toxicol. 2017 Aug;71:118-123. doi: 10.1016/j.reprotox.2017.05.002. Epub 2017 May 10.

16.

Altered functional resting-state hypothalamic connectivity and abnormal pituitary morphology in children with Prader-Willi syndrome.

Lukoshe A, van Dijk SE, van den Bosch GE, van der Lugt A, White T, Hokken-Koelega AC.

J Neurodev Disord. 2017 Feb 21;9:12. doi: 10.1186/s11689-017-9188-7. eCollection 2017.

17.

Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.

Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hübner C, Hokken-Koelega AC; KIGS Steering Committee.

J Clin Endocrinol Metab. 2017 May 1;102(5):1702-1711. doi: 10.1210/jc.2016-2962.

PMID:
28323917
18.

The syndrome of central hypothyroidism and macroorchidism: IGSF1 controls TRHR and FSHB expression by differential modulation of pituitary TGFβ and Activin pathways.

García M, Barrio R, García-Lavandeira M, Garcia-Rendueles AR, Escudero A, Díaz-Rodríguez E, Gorbenko Del Blanco D, Fernández A, de Rijke YB, Vallespín E, Nevado J, Lapunzina P, Matre V, Hinkle PM, Hokken-Koelega AC, de Miguel MP, Cameselle-Teijeiro JM, Nistal M, Alvarez CV, Moreno JC.

Sci Rep. 2017 Mar 6;7:42937. doi: 10.1038/srep42937.

19.

Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.

Swerdlow AJ, Cooke R, Beckers D, Borgström B, Butler G, Carel JC, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse E, Gausche R, Giacomozzi C, Hokken-Koelega ACS, Khan AJ, Kiess W, Kuehni CE, Mullis PE, Pfaffle R, Sävendahl L, Sommer G, Thomas M, Tidblad A, Tollerfield S, Van Eycken L, Zandwijken GRJ.

J Clin Endocrinol Metab. 2017 May 1;102(5):1661-1672. doi: 10.1210/jc.2016-2046.

20.

Effects of size at birth, childhood growth patterns and growth hormone treatment on leukocyte telomere length.

Smeets CC, Codd V, Denniff M, Samani NJ, Hokken-Koelega AC.

PLoS One. 2017 Feb 8;12(2):e0171825. doi: 10.1371/journal.pone.0171825. eCollection 2017.

Supplemental Content

Loading ...
Support Center